VolitionRX (NYSEAMERICAN:VNRX) Stock Price Passes Below 50 Day Moving Average – Should You Sell?

Shares of VolitionRX Limited (NYSEAMERICAN:VNRX) crossed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $0.25 and traded as low as $0.1922. VolitionRX shares last traded at $0.20, with a volume of 678,812 shares traded.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on VNRX shares. Maxim Group lowered VolitionRX from a “buy” rating to a “hold” rating in a research note on Wednesday, December 3rd. D. Boral Capital reaffirmed a “buy” rating and issued a $3.00 price objective on shares of VolitionRX in a report on Wednesday, January 21st. Finally, HC Wainwright lowered their price objective on VolitionRX from $2.50 to $1.50 and set a “buy” rating on the stock in a research report on Monday, November 17th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, VolitionRX presently has a consensus rating of “Buy” and a consensus target price of $2.50.

VolitionRX Stock Down 2.9%

The company’s fifty day moving average price is $0.25 and its 200 day moving average price is $0.38. The company has a market capitalization of $25.81 million, a P/E ratio of -0.83 and a beta of 1.33.

Institutional Trading of VolitionRX

Several large investors have recently modified their holdings of the stock. Virtu Financial LLC bought a new position in shares of VolitionRX in the third quarter worth $28,000. Northwestern Mutual Wealth Management Co. acquired a new position in VolitionRX in the second quarter valued at about $52,000. Jane Street Group LLC bought a new stake in VolitionRX during the fourth quarter worth about $28,000. Squarepoint Ops LLC bought a new stake in VolitionRX during the fourth quarter worth about $34,000. Finally, Silverberg Bernstein Capital Management LLC grew its stake in VolitionRX by 15.6% during the third quarter. Silverberg Bernstein Capital Management LLC now owns 232,082 shares of the medical research company’s stock worth $157,000 after buying an additional 31,300 shares in the last quarter. 8.09% of the stock is owned by institutional investors and hedge funds.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.